A federal judge has refused to stay the upcoming trial in a reverse-payment settlement antitrust case while the remaining defendants await the Third Circuit's review of a class certification ruling.

Trial is scheduled to begin Feb. 2, 2016, in the case King Drug Co. of Florence v. Cephalon, a long-running suit by several different classes of plaintiffs who argued the reverse-payment settlements Cephalon entered with four generic pharmaceutical companies to delay the entry of a generic version of Provigil to market was anti-competitive and caused them to pay more for the drug.

The suit and related litigation over the Provigil settlements have resulted in a number of settlements of its own, including some of the parties to this suit previously settling for $512 million and the Federal Trade Commission settling similar claims against Cephalon for a record $1.2 billion. And the judge overseeing the case, U.S. District Judge Mitchell Goldberg of the Eastern District of Pennsylvania, has denied class certification to certain plaintiff groups.